monoclonal antibody combination
Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA
Globally, around 150 to 200 out of every million people have myasthenia gravis
Regeneron agrees research collaboration with Parabilis Medicines
Regeneron will pay Parabilis $125m upfront, with up to $2.2bn in potential milestone payments and royalties
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
Regeneron’s Libtayo receives EC approval for skin cancer
Phase 3 trial results showed the drug significantly improved disease-free survival
Invivyd working with FDA towards potential Biologics License Application for COVID-19
The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment
FDA approves Pfizer and BioNTech’s jab for COVID-19
Globally, five billion doses of the companies’ vaccine have been distributed
Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP
Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1
Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid
Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease
Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones
These are the first clinical study results for the drug in a large population of patients with darker skin tones
Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma
More than 35,000 new cases of the blood cancer are diagnosed in Europe every year